Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
McKesson
Dow
Boehringer Ingelheim
Moodys

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Imeglimin


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Imeglimin?

Imeglimin is an investigational drug.

There have been 6 clinical trials for Imeglimin. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2013.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Liver Diseases. The leading clinical trial sponsors are Poxel SA and [disabled in preview].

There are thirty-one US patents protecting this investigational drug and three hundred and forty-five international patents.

Recent Clinical Trials for Imeglimin
TitleSponsorPhase
Pharmacokinetics of Imeglimin in Hepatic Impaired SubjectsPoxel SAPhase 1
Bioequivalence of Imeglimin Tablet FormulationsPoxel SAPhase 1
Effect of Cimetidine on the PK of ImegliminPoxel SAPhase 1

See all Imeglimin clinical trials

Clinical Trial Summary for Imeglimin

Top disease conditions for Imeglimin
Top clinical trial sponsors for Imeglimin

See all Imeglimin clinical trials

US Patents for Imeglimin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Imeglimin ⤷  Try it Free Biguanide compositions and methods of treating metabolic disorders ELCELYX THERAPEUTICS, INC. (San Diego, CA) ⤷  Try it Free
Imeglimin ⤷  Try it Free Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Try it Free
Imeglimin ⤷  Try it Free Biguanide compositions and methods of treating metabolic disorders ELCELYX THERAPEUTICS, INC. (San Diego, CA) ⤷  Try it Free
Imeglimin ⤷  Try it Free Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk ELCELYX THERAPEUTICS, INC. (San Diego, CA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Imeglimin

Drugname Country Document Number Estimated Expiration Related US Patent
Imeglimin Argentina AR091089 2031-01-07 ⤷  Try it Free
Imeglimin Argentina AR091739 2031-01-07 ⤷  Try it Free
Imeglimin Australia AU2011317140 2030-10-19 ⤷  Try it Free
Imeglimin Australia AU2011317143 2030-10-19 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
McKesson
Dow
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.